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Abstract 
Our previous studies have demonstrated that platelets possess ATP purinergic receptors in addition to the ADP, P2T, receptor. 
Occupancy of the P2 receptor by ATP inhibited agonist-induced platelet aggregation. This study demonstrated that the mechanism of 
inhibition may involve ATP inhibition of agonist-induced mobilization of internal calcium. Within the cardiovascular system, the ATP 
inhibition of calcium mobilization is unique to platelets. All other cell types in the cardiovascular system, where calcium mobilization is
affected by extracellular ATP, responded with an increased mobilization as opposed to inhibition. The platelet inhibitory response to ATP 
was enhanced by the addition of an ATP generating system, creatine phosphate/phosphocreatine kinase. ATP and ATP analogues were 
found to inhibit calcium mobilization with a rank order of aft-methylene ATP, f/y-methylene ATP = ATP > benzoyl ATP> 2 
methylthio ATP which is a characteristic of P2x-like receptors. The inhibitory effect of ATP could be abrogated by prolonged treatment of 
platelets with the P2x desensitizing agent, aft-methylene ATP. Also, UTP and CTP were approximately aseffective inhibitors as ATP 
while GTP was not. ATP competition with ADP for the P2T receptor was excluded in studies with platelets derived from an 
aspirin-treated individual which were essentially insensitive to ADP. The agonist-induced calcium mobilization and inhibition by ATP 
occurred with the thromboxane A 2 mimetic, U46619, collagen and thrombin; however, the kinetics of mobilization varied somewhat with 
the different agonists. The responses to extracellular ATP were independent of extracellular Ca 2+, where 1 mM calcium or 0.3 mM 
EGTA was added to the reaction mixture. The inhibition of calcium mobilization coupled to inhibition of platelet aggregation by 
extracellular ATP may serve an important physiologic role. ATP, released from activated platelets at localized sites of vascular injury, 
may help to limit the size of the platelet plug-clot hat, if left unregulated, could occlude the injured blood vessel. 
1. Introduction 
It has been proposed that calcium is involved in virtu- 
ally all cellular processes associated with platelet activa- 
tion [1]. Mobilization of intracellular pools of calcium, 
[ Ca2+ ]i, is associated with platelet shape change and ag- 
gregation [2,3], while extracellular calcium also contributes 
significantly to platelet function [3,4]. The mobilization of 
intracellular platelet pools of Ca 2 ÷ is associated with the 
agonist-induced G protein-coupled activation of phospho- 
lipase C and the production of inositol trisphosphate (IP 3) 
[5]. However, in the platelet other pathways also appear to 
function since ADP-induced [Ca2+]i mobilization occurs 
in the absence of IP 3 generation [6]. While mobilization of 
[Ca2+] i pools is associated with agonist-induced platelet 
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activation [1,3-5], agents or actions that stimulate an 
increase of intracellular cAMP levels generally inhibit 
platelet activation and inhibit [Ca2+] i mobilization [5,7- 
11]. In many other cell systems the converse is true, the 
stimulation of cAMP is directly [12,13] or indirectly [14,15] 
associated with [Ca 2÷ ]i mobilization. The ability of cAMP 
to inhibit agonist-induced [Ca 2+ ]i mobilization in platelets 
may result, in part, or completely, from the phosphoryla- 
tion and inactivation of the endoplasmic reticulum IP 3 
receptor protein required for Ca 2÷ release [11]. Phospho- 
rylation of Gin associated with phospholipase C also ap- 
pears to inhibit enzyme activation resulting in reduced IP 3 
formation and [Ca~ + ] mobilization via a protein kinase 
C-dependent pathway [16]. 
Calcium and ATP are released, along with many other 
compounds, from activated platelets [17]. The small quan- 
tities of intracellular calcium released to the extracellular 
environment would only negligibly alter the pre-existing 
74 Gerald Soslau et al. / Biochimica et Biophysica Acta 1268 (1995) 73-80 
millimolar calcium concentration. However, the ATP re- 
leased into a virtually nucleotide-free nvironment, reach- 
ing levels of 20 /xM [18] to 50 ~M [19] at sites of 
vascular injury along with its subsequent hydrolysis to 
adenosine, could significantly impact on local cell func- 
tions. The autocrine and paracrine roles of this extracellu- 
lar ATP in regulating platelet function has only recently 
begun to be explored [20,21]. Early studies demonstrated 
that ATP competition with ADP for binding to the ADP 
receptor inhibited platelet aggregation [22]. However, the 
perception that this was the sole mechanism of action has 
been revised based upon more recent work that has defined 
a second mechanism involving a specific platelet ATP 
receptor [21]. 
The pioneering studies that established the presence of 
cell surface ATP receptors, classified as P2 purinoceptors 
(reviewed in Ref. [23]), have been expanded upon during 
the past two decades to demonstrate a broad spectrum of 
intracellular responses to ATP occupancy of these receptor 
types [19,23-26]. Extracellular ATP can selectively bind 
to cell surface P2x, PEr, P2z [23,26] and other possible P2 
receptor subtypes [19,21,27-29] within the cardiovascular 
system. A response common to all previously reported 
cardiovascular cells to extracellular ATP is the mobiliza- 
tion of [Ca 2+ ]i [27-33]. Mobilization of [Ca2+]i in these 
cell types appears to involve occupancy of P2v receptors 
with the activation of phospholipase C and the generation 
of IP 3 [34-36]. A recent report describes the inhibition of 
[ Ca2+ ]i mobilization in rat submandibular cini by extra- 
cellular ATP mediated by a P2z receptor [37]. ATP in- 
duced influx of calcium through ligand selective receptor 
pores or ion channels represent other potential mechanisms 
associated with the regulation of intracellular calcium lev- 
els [19]. 
Platelets possess an apparently unique P2x-like receptor 
that when occupied inhibits agonist-induced aggregation 
by a G protein coupled pathway that stimulates cAMP 
levels [21]. The present study demonstrates that extracellu- 
lar ATP also inhibits [Ca2+] i mobilization, contrary to 
other cellular systems where it stimulates mobilization. 
The extracellular ATP inhibition of agonist-induced aggre- 
gations previously described [20,21] appears to be associ- 
ated, at least in part, with the reduced level of intracellular 
Ca 2÷ mobilization observed in the present study. The ATP 
inhibition of [Ca~ + ] mobilization is independent of extra- 
cellular Ca 2÷ and released ADP. The differential responses 
to extracellular ATP of platelets versus other cardio- 
vascular cells may be significant in regulating vascular 
tone and hemostasis at sites of vascular injury. 
1.1. Material and methods 
Platelet preparation and Fura 2 loading 
Blood (20-50 ml) was drawn from normal healthy 
volunteers (each signed consent forms in accordance with 
The University Human Studies Committee) by venipunc- 
ture and platelet-rich plasma (PRP) prepared as previously 
described [38]. Platelets, in PRP, were incubated for 45-60 
min with Fura-2AM (Molecular Probes) adjusted to 1 /xM. 
Fura-2 loaded platelets were then gel-filtered or washed 
for the calcium studies to remove unincorporated Fura-2. 
Some platelet preparations were passed through a 23-ml 
Sepharose CL-2B packed column freshly equilibrated with 
Hepes Tyrode's buffer (3.8 mM Hepes, 136 mM NaC1, 2.7 
mM KCI, 3.3 mM Nail  2 PO4, 1 mM MgC12 [pH 7.35]) 
plus 1 mg/ml each of bovine serum albumin (BSA) and 
dextrose. Other platelet preparations were washed by dilut- 
ing the PRP with 3 volumes of a citrate buffer (10 mM 
Tris, 150 mM NaC1, 100 mM sodium citrate [pH 6.0]), 
pelleting at 400 × g for l0 min and resuspending in Hepes 
Tyrode's buffer with BSA and dextrose as described above. 
Platelet concentrations varied between 2 and 3. l08 
cells/ml. 
Platelet aggregation 
Washed or gel-filtered platelets were employed to ascer- 
tain their ability to aggregate in response to selected 
agonists. Platelet aggregation was measured as percent 
change in light transmission on a Chronolog aggregometer 
(Havertown, PA) exactly as described previously [39]. 
Internal calcium mobilization 
All experiments were carried out using 0.5-ml aliquots 
of the platelet suspension i  a special quartz microcuvette 
with 4.5-mm path length, and 0.8-ml maximum volume 
maintained at 37°C in a Hitachi F-2000 fluorescence 
spectrophotometer with magnetic stirrer and injection port 
essentially as previously reported [40]. All subsequent 
additions were made through the injection port. Excitation 
wavelengths were 340 nm and 380 nm, and emission was 
measured at 505 nm. Minimal contributions by autofluo- 
rescence (measured in suspensions of unloaded platelets) 
were automatically subtracted from the fluorescence val- 
ues, and the instantaneous ratio of emission at 505 nm with 
excitation at 340 nm and 380 nm was calculated. Ca 2+ 
concentration was calculated using the formula: 
Ratio - emi n Fmin(WL2) - Z2(WL2) 
[ Ca2 + ]i * * K 
Rma x -- Ratio Fmax(WL2 ) - ZZ(WL2)  
WL1 - ZI(WL1) 
Ratio = 
WL2 - Z2(WL2) 
Fmin( WL1 - Z1 ( WL1 ) 
gmin = F~, (WL2)  - Z2(WL2) 
Fmax(WL1 ) - Z I (WL1)  
gmax = Fmax(WZ2) - Z2(WL2) 
K = dissociation constant o fFura  - 2 (224 nM)  
Z = autofluorescence at WL1 or WL2 (wavelengths)  
Calibration of our particular system using mixtures of 
EGTA and CaEGTA (zero and 10 mM CaEGTA) with the 
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pentapotassium salt of Fura-2 gave a nearly perfect linear 
response between 16.7 nM Ca 2+ and 1.35 mM Ca 2+. Plots 
of log [Ca 2+ ] (calculated) vs. log [Ca 2+ ] (measured) 
showed that the measured values were consistently about 
1-2% higher than the calculated values. Calibrations using 
4-bromo A23187 or ionomycin to equilibrate internal and 
external Ca 2+ of platelets in known concentrations of 
external calcium gave similar results. The average internal 
resting concentration of free [Ca 2+ ] for 26 samples _+ the 
standard eviation was 21.4 _+ 4.8 nM. 
Statistics 
Data presented in the table were analyzed by Student's 
t-test for controls and a single variable (ATP) which were 
being compared to each other. However, in all of the other 
studies where multiple variables were being compared to 
the control, along with variations in sample size, data were 
analyzed by one-way analysis of variance and then the 
individual groups compared to each other by the Bonfer- 
roni t-test. Significance was set at a P-value of < 0.05. 
2. Results 
Mobilization of intracellular platelet calcium 
Sequestered intracellular Ca 2 + is mobilized by extracel- 
lular platelet agonists and is an intimate participant in the 
subsequent activation-aggregation of the platelets. The ag- 
onists employed in these studies, thrombin, collagen, ADP 
and the thromboxane A 2 mimetic, U46619, all induced 
[ Ca2+ ]i mobilization, as also shown by others, to varying 
degrees and with different kinetics (Fig. 1). Thrombin (0.2 
U/ml)  induced the greatest mobilization effect while col- 
lagen (42 /zg/ml) and ADP (10 /xM) were the weakest 
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Fig. 1. A comparison of different platelet agonist-induced mobilizations 
of internal calcium. The mobilization of [Ca 2÷ ]i was measured in Fura-2 
loaded platelets in response to thrombin (0.2 U/ml), U46619 (1 /zM), 
collagen (42 tzg/ml) or ADP (10 /zM), as described in Section 2. 
Mobilization is presented as difference from baseline values. 
Table 1 
Quantitation of the extracellular ATP inhibition of [Ca 2+ ]i mobilization 
Agonist Increase in [Ca 2+ ]i Mean % Significance 
(nM) inhibition (P)  paired 
T (0.2 U/ml)  148.9+7.6 (11) 
A (90-360/.~M)+ T 100.4+7.4(11) 32.6 4.10e -5 
U (1 /zM) 71.9+6.6 (9) 
A (90-360/~M)+U 31.0+5.6 (9) 56.9 2.37e -5 
C (42 /.tg/ml) 39.1 + 7.1 (8) 
A (180-360/zM)+C 22.2+2.4 (8) 43.2 0.035 
T, thrombin; A, ATP; U, U46619; C, collagen. Data are presented as: 
means _ S.E.M. (number of determinations). Statistics are paired Student's 
t-tests. 
inducers. All reactions were conducted in the absence of 
added calcium or fibrinogen. Both thrombin and U46619 
(1 /zM) induced a very rapid [Ca2+]i release with the 
virtually complete resequestration f Ca 2÷ having oc- 
curred more rapidly with U46619. The rates of release and 
resequestration f Ca 2+ was independent of extracellular 
Ca 2÷ since the response to agonist remained the same in 
the presence of added 1 mM Ca 2÷ or 0.3 mM EGTA to 
deplete xtracellular Ca 2+. 
ATP inhibition of [Ca 2 + ]i mobilization 
We demonstrated previously that extracellular ATP in- 
hibits agonist-induced platelet aggregation, atleast in part, 
by inducing intracellular cAMP levels [20,21]. We there- 
fore extended these studies to determine if extracellular 
ATP also inhibited [Ca 2+ ]i mobilization in platelets as 
opposed to its stimulatory action observed in numerous 
other cell systems. The quantitation of the extracellular 
ATP inhibition of [Ca2+] i mobilization is presented in 
Table 1. In each case the ATP-treated versus control 
sample was significantly different, whether analyzed by an 
independent or paired Student's t-test. In several studies 
where increasing concentrations of extracellular ATP or 
the ATP analogue, /3yATP, were added to a single platelet 
preparation there was a dose-response observed. One such 
experiment with /3yATP is depicted in Fig. 2. However, 
80 
60 
Thrornbin 
20 /~/ 
0.0 0.2 0.4 0.6 0.8 1.0 
pyATP (rnM) 
Fig. 2. Inhibition of thrombin-or U46619-induced [Ca 2+ ]i mobilization 
by increasing doses of extracellular/3yATP. The % inhibition by/37ATP 
of agonist-induced [Ca 2+ ]i mobilization was determined relative to con- 
trois in the absence of /3yATP in Fura-2-1oaded platelets. 
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the difference in the level of inhibition between concentra- 
tions of 90 to 360 /zM were typically in the 10-20% 
range. The ATP-induced inhibition appeared to plateau 
after the addition of 100-400 /~M ATP. 
ATP analogues and other nucleotide triphosphates 
ATP and selected ATP analogues inhibited thrombin 
and U46619-induced [Ca2+] i mobilization with an ex- 
pected rank order implicating the presence of P2x-like 
receptors as we have previously reported [21]. The order 
follows o~/3ATP =/3TATP = ATP > BzATP > 2MeS ATP 
(Fig. 3A). Only ATP, a/3ATP and /3TATP showed signif- 
icant inhibition of agonist-induced [Ca2+] i mobilization. 
The 2MeS ATP showed no inhibition even at the maxi- 
mum concentration tested of 500 /zM (data not shown). 
Also, as we previously described for platelet aggregations 
[21], UTP and CTP are equally or more effective inhibitors 
of calcium mobilization than ATP (all with P < 0.05 
relative to control), while GTP is the least effective nu- 
cleotide triphosphate inhibitor (Fig. 3B). 
ATP regenerating system and ATP analogues 
The analysis of extracellular ATP inhibition of agonist- 
induced [Ca2+] i mobilization may be complicated by the 
hydrolysis of ATP to adenosine (ATP- > ADP- > AMP- > 
adenosine) which also inhibits mobilization. This ambigu- 
ity is reduced by the use of poorly hydrolyzable ATP 
analogues, as above. A second means of analyzing the 
ATP effect in the absence of hydrolysis is to add an ATP 
regenerating system to the reaction mixture. A mixture of 
1.7 mM creatinine phosphate (CP) and 2.7 U phosphocrea- 
tinine kinase (CPK) was employed for these studies. The 
ATP regenerating system alone had little effect on platelet 
aggregations (data not shown) or [Ca2+]i mobilizations. 
Repeated experiments demonstrated that ATP and /37 ATP 
in the presence of the ATP regenerating system continued 
to be significantly inhibitory while 2MeS ATP was with- 
out effect (Fig. 4). 
The interaction of ATP and ATP analogues with a 
Pe×-like receptor was further substantiated by the desensiti- 
zation of this receptor with the P2x agonist, a/3ATP [41]. 
Fig. 5 depicts the reduced ability of c~/3ATP and /3TATP 
to inhibit thrombin-induced [Ca 2+ ]i mobilization with pro- 
longed periods of exposure to a/3ATP. Multiple thrombin 
controls were run where the level of [Ca 2+ ]i mobilization 
was normalized to 100% and each experimental point was 
then compared to its control. Similar results were observed 
with platelet aggregation studies [21]. 
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Fig. 3. Agonist-induced mobilization f [Ca 2+ ]i in the absence orpresence of ATP, ATP analogues or ribonucleotide triphosphates. (A) The level of 
[Ca2+]i mobilized in platelets reated with thrombin (0.1 U/ml) or U46619 (1 /~M) in the absence orpresence of 200 /xM ATP or ATP analogues: 
a/3 = c~/3ATP; /3 y =/3yATP; Bz = BzATP and 2 MeS = 2MeS ATP. The level of [Ca :+ ]i mobilization in the presence ofcontrol thrombin or U46619 
was normalized to 100 with each experimental point reported as relative values compared to its control. The control mean _+ S.E.M. (number of 
determinations) for thrombin was 97.0 + 17.4 [5] and for U46619 itwas 88.5 + 13.7 [11 ]. (B) [Ca 2 + ]i mobilization was determined as in panel (A) in the 
absence or presence of 200 /xM: ATP (A); CTP (C); UTP (U) or; GTP (G). The control values for thrombin was 54.0 + 6.2 [4] and for U46619 it was 
78.9 + 8.1 [9]. All data in the figure are presented asmean + SEM with sample numbers inparentheses. The asterisk (*) denotes P < 0.05 relative to 
controls as described inSection 2. 
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ADP versus ATP receptor 
Conditions were established to minimize any potential 
contribution of ADP to platelet activation. This would then 
allow one to ascertain the role of extracellular ATP bound 
to its selective P2x-like receptor in the absence of competi- 
tion for the ADP receptor, P2T- Blood was collected from a 
healthy volunteer after the. subject had taken 1 950 mg 
aspirin per day for 4 days. The platelets were loaded with 
Fura-2, washed as described in Section 2 and a portion 
used for platelet aggregations or [Ca 2÷ ]i mobilization. 
Fig. 6A demonstrates that the Fura-2 loaded, washed 
platelets were not aggregated in response to 10 /zM ADP 
while they were by 0.05 U /ml  thrombin. ADP, alone, 
induced a small platelet shape change but neither stimu- 
lated nor inhibited thrombin-induced aggregation when 
added simultaneously with thrombin. However, 100 /zM 
/3TATP inhibited thrombin-induced aggregation approxi- 
mately 50%. This same platelet preparation was used to 
follow [Ca 2+ ]i mobilizations (Fig. 6B). The ADP induced 
a rapid increase in [Ca2+]i mobilization followed by the 
rapid resequestration of Ca 2+. This shape change related 
[ Ca2÷ ]i mobilization was completely abrogated by flTATP. 
When ADP was added simultaneously with thrombin the 
[ Ca2 + ]i mobilization profile was the equivalent of the ADP 
and thrombin profiles added together. Therefore, released 
ADP from platelet dense granules did not contribute to 
either aggregation or [Ca:'+]~ mobilization induced by 
thrombin alone. Our previous tudies demonstrated platelets 
contain 1.23 • 10  -9  mg protein per platelet [38] and 11.74 
nmol /mg granule protein [42]. Assuming our granule 
preparation contained one-tenth of the total platelet con- 
tent, the maximum releasable ADP from 0.5 ml samples of 
1-1.5 × 108 platelets wouM be 0 .2-0 .4/zM.  ADP (1-10 
/xM) induced a dose-response release of [Ca2+] i with 
essentially zero mobilization at 1 /zM (data not shown). 
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Fig. 4. U46619-induced mobilization of [Ca 2+ ]i in the absence or 
presence of ATP or ATP analogaes with an added ATP regenerating 
system. The relative level of [Ca 2 + ]i mobilization (as described inFig. 3) 
induced by 1 /zM U46619 was determined with creatine phosphate (1.7 
mM) plus creatine phosphokinase (2.7 U/ml) added to each reaction 
along with 200 /xM ATP or ATP analogues, where present. /33,ATP is 
represented as /33' and 2MeS ATP as 2MeS. All data are presented as in 
Fig. 3. The control value for U46619 + CP/CPK was 142.8 + 6.7 [5]. 
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Fig. 5. Desensitization of the platelet P2x-like purinoceptor by a/3ATP. 
Thrombin (0.1 U/ml)- induced [Ca 2+ ]i mobilization was normalized to 
100% and the relative concentrations of mobil ized calcium presented 
after zero (0') to 30 min (15',30') exposure to 100 p~M cz/3ATP (a , /3 )  
with or without the addition of 100 /xM /33'ATP ( /33') just  prior (0') to 
the addition of thrombin. 
This further supports the conclusion that ADP released 
from our thrombin-treated platelet preparations did not 
contribute to calcium mobilization. When flTATP was 
added just prior to the thrombin it inhibited [Ca 2+ ]i mobi- 
lization approximately 40% which was comparable to the 
flTATP effect on aggregation. 
3. Discussion 
Human platelets possess a surface ATP receptor in 
addition to the ADP (P2x) receptor. Our studies demon- 
strated that ATP, binding to an unique platelet P2 receptor, 
inhibits agonist-induced mobilization of intracellular cal- 
cium, [Ca 2÷ ]i, unlike all other cells in the cardiovascular 
system. Platelets are a major source of extracellular ATP, 
released upon activation, at localized regions of vascular 
injury. ATP is also released into the cardiovascular system 
from endothelial and cardiac cells during hypoxia [24,43]. 
Extracellular ATP then impacts on platelets and nearby 
cells in an autocrine and paracrine fashion. Endothelial 
cells and all of the other blood cells studied to date contain 
P2 receptors which when occupied with extracellular ATP 
results in mobilization of [Ca 2+ ]i via a G-protein coupled 
activation of phospholipase C and generation of IP 3 or 
permits the influx of extracellular Ca 2+ through selective 
pores or ion channels [19]. The increased level of 'free' 
intracellular calcium in these cell types produces a variety 
of responses. If a similar calcium response were to occur 
in platelets, the released ATP would continuously activate 
newly recruited platelets resulting in the production of 
aggregates that could occlude the injured blood vessel. 
The distinct response of platelets to extracellular ATP, 
previously described [20,21], was further reflected in the 
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ATP inhibition of agonist-induced mobilization of [Ca 2 + ]i- 
The mobilization of [Ca 2+ ]i in many cell types is enhanced 
by activation of protein kinase C (PKC) [44,45] and/or 
may be accompanied by increased levels of cAMP [12- 
15,46]. Mobilization of [Ca2+]i in platelets, on the other 
hand, is inhibited by increased production of cAMP [5,7- 
11] and PKA or PKC inhibit [Ca2+] o influx [5]. It is 
presumed that the mode of action of extracellular ATP 
inhibition of [Ca 2+ ]i mobilization in platelets presented in
this report was, in part, due to the ATP-induced increase of 
intracellular cAMP previously described [20,21 ]. The inhi- 
bition of [Ca2+]i mobilization may also involve PKA-in- 
duced phosphorylation of the IP 3 receptor [11] and the 
enhanced reuptake of calcium by the dense tubules [10]. 
Results with platelets derived from an individual on 
aspirin demonstrated two distinct [Ca 2+ ]i mobilization pat- 
terns for 10 /zM ADP versus 0.05 U/ml  thrombin. ADP, 
under these conditions, induced platelet shape change 
without aggregation which was accompanied by a very 
rapid increase in [Ca2+] i mobilization and subsequent 
rapid resequestration f calcium. Thrombin, on the other 
hand, induced platelet aggregation which was associated 
with a slower but larger rise in [Ca 2+ ]i mobilization and a 
much slower resequestration f calcium than ADP. When 
ADP and thrombin were added simultaneously, the pattern 
of [Ca2+] i mobilization was simply the addition of the 
platelet response observed for each agonist alone. Further- 
more, the simultaneous addition of ADP and thrombin did 
not increase the level of platelet aggregation as compared 
to thrombin alone. Therefore, one could conclude that the 
level of [Ca2+]i mobilization induced by thrombin alone 
was independent of the small amount of ADP that would 
be released uring thrombin-induced platelet aggregation. 
The 40% inhibition of thrombin-induced [Ca 2÷ ]i mobiliza- 
tion by extracellular ATP cannot be due to competition for 
the P2T receptor with ADP but rather the ATP must be 
acting at a selective ATP receptor. Therefore, while ATP 
modulates platelet functions by interacting with its specific 
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Fig. 6. Platelet aggregation and [Ca 2+ ]i mobilization induced by thrombin, ADP or thrombin plus ADP and the effect of fly ATP. (A) 10/zM ADP-, 0.05 
U/ml  thrombin-, or, ADP + thrombin-induced platelet aggregation i the presence or absence of 100/xM fl-yATP. (B) The mobilization of [Ca 2+ ]i under 
the identical conditions depicted in panel (A). 
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P2 receptor, it also competes with ADP for its P2T recep- 
tor, as we and others have shown for ADP-induced aggre- 
gation. ATP presumably, also competitively inhibits ADP- 
induced [Ca 2÷ ]i mobilization as seen in this study. 
The inhibition of agonist-induced [Ca2+] i mobilization 
by ATP bound to a P2x-like receptor may be indicated by 
the rank order of reactivities with ATP analogues: a/3ATP, 
fl3~ATP = ATP > Bz ATP > 2MeS ATP [24,25]. Further 
evidence for the P2x-like nature of the ATP receptor comes 
from the ability to desensitize the response to ATP by 
prolonged exposure of platelets to the P2x desensitizing 
agent ceflATP [41]. However, the inhibitory response of 
[Ca+2] i mobilization to nucleotide triphosphates, which 
paralleled our previous observations [21] of inhibition of 
platelet aggregation: ATP -- UTP = CTP >> GTP, could 
possibly implicate a P2u-like receptor. The inhibitory re- 
sponse to extracellular ATP was not due to a hydrolyzed 
product of ATP since inhibition was observed in the 
presence of an ATP-regenerating system as well as with 
poorly hydrolyzable ATP analogues. The platelet P2 recep- 
tor appears to be distinct from the P2u receptor ecently 
described in a human meg;akaryocytic cell line [47]. The 
distribution of surface purinoceptors may change with 
maturation of the megakaryocyte with the platelet ATP P2 
receptor being a marker for late or terminal maturation. 
The exact identification of the platelet ATP receptor and 
its mode of action must await cloning and comparison to 
cloned P2u [48,49], P2Y [50,51] and P2x [52,53] receptors. 
The unique action of extracellular ATP on platelets 
makes good teleological sense. While extracellular ATP, 
released from activated p}[atelets, timulates diverse cell 
types within the cardiovascular system to promote heal- 
ing/repair processes it acts as a regulatory brake on 
platelets to prevent excessive platelet plug formation. An 
analogous ystem has recently been reported where ATP, 
released from autonomic nerve terminals, inhibits [Ca 2+ ]i 
mobilization in cells under autonomic ontrol [37]. This 
system, like ours, was independent of external Ca2+; how- 
ever, they found that ATP interacted with a P2z receptor 
which was insensitive to other nucleotide triphosphates, 
ADP or adenosine. 
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